Literature DB >> 2447319

Tumor necrosis factor inhibiting angiogenesis in vitro.

N Sato1, K Fukuda, H Nariuchi, N Sagara.   

Abstract

The effect of recombinant human tumor necrosis factor (TNF) on the capillary growth was evaluated using an in vitro angiogenesis model recently developed. Sprague-Dawley rat microvessel fragments, from epididymal fat pads, seeded onto the confluent culture of myofibroblastic cells from the same tissue origin, gave rise to microvascular networks on and in the multilayered myofibroblastic cells. In contrast, the capillary growth from the vessel fragments was markedly inhibited in the presence of 10-1,000 U TNF/ml. Monoclonal antibody against TNF completely neutralized the capillary growth inhibitory activity of TNF. The mode of angiogenesis inhibitory action of TNF was also examined by use of bovine capillary endothelial (BCE) cells and rat myofibroblastic cells. TNF exerted growth inhibitory and cytotoxic actions against BCE cells cultivated on the various basement membrane components, such as extracellular matrix secreted by BCE cells, fibronectin, laminin, and type IV collagen. An irreversible damage to most of the BCE cells was observed ultrastructurally after 60 hours' exposure to TNF. TNF, however, did not injure the myofibroblastic cells but rather stimulated their growth. These findings indicate that TNF inhibits in vitro capillary growth by its direct cytostatic and cytotoxic actions to microvascular endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2447319

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

1.  Platelet-derived growth factor indirectly stimulates angiogenesis in vitro.

Authors:  N Sato; J G Beitz; J Kato; M Yamamoto; J W Clark; P Calabresi; A Raymond; A R Frackelton
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

2.  Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis.

Authors:  S Yoshida; M Ono; T Shono; H Izumi; T Ishibashi; H Suzuki; M Kuwano
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

3.  Effect of endurance training on angiogenic activity in skeletal muscles.

Authors:  H Yamashita; N Sato; M Yamamoto; S Gasa; T Izawa; T Komabayashi; M Ishikawa; Y Sato; H Ohno
Journal:  Pflugers Arch       Date:  1993-01       Impact factor: 3.657

4.  Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy.

Authors:  Tom A Gardiner; David S Gibson; Tanyth E de Gooyer; Vidal F de la Cruz; Denise M McDonald; Alan W Stitt
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

5.  Tumor necrosis factor-α signaling via TNFR1/p55 is deleterious whereas TNFR2/p75 signaling is protective in adult infarct myocardium.

Authors:  Raj Kishore; Tengiz Tkebuchava; Sharath P Sasi; Marcy Silver; Hu-Ya Gilbert; Young-Sup Yoon; Hee-Young Park; Tina Thorne; Douglas W Losordo; David A Goukassian
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

6.  Genetic deletion of TNFR2 augments inflammatory response and blunts satellite-cell-mediated recovery response in a hind limb ischemia model.

Authors:  Sharath P Sasi; Layla Rahimi; Xinhua Yan; Marcy Silver; Gangjian Qin; Douglas W Losordo; Raj Kishore; David A Goukassian
Journal:  FASEB J       Date:  2014-12-02       Impact factor: 5.191

7.  A phase II combination trial with recombinant human tumor necrosis factor and gamma interferon in patients with colorectal cancer.

Authors:  W Fiedler; W Zeller; C J Peimann; H J Weh; D K Hossfeld
Journal:  Klin Wochenschr       Date:  1991-04-04

8.  Dual role of tumor necrosis factor-alpha in angiogenesis.

Authors:  L F Fajardo; H H Kwan; J Kowalski; S D Prionas; A C Allison
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

9.  Breaking the 'harmony' of TNF-α signaling for cancer treatment.

Authors:  S P Sasi; X Yan; H Enderling; D Park; H-Y Gilbert; C Curry; C Coleman; L Hlatky; G Qin; R Kishore; D A Goukassian
Journal:  Oncogene       Date:  2011-12-12       Impact factor: 9.867

10.  The acute phase reactant orosomucoid-1 is a bimodal regulator of angiogenesis with time- and context-dependent inhibitory and stimulatory properties.

Authors:  Giovanni Ligresti; Alfred C Aplin; Bruce E Dunn; Ann Morishita; Roberto F Nicosia
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.